Evidence map›Paper›PMID 42553398›Full record

ArticleFrontiers in immunology2026

Targeting stroma-mediated T-cell exclusion and functional exhaustion in pancreatic ductal adenocarcinoma through CXCR4 and PD-1 blockade.

Alina Deipenbrock, Lina Hofer, Ben E Wilmes, Timur Cetin, Irene Esposito, Dirk Weyhe, Johannes Stegmaier, Nicole E Teusch

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alina DeipenbrockHeinrich-Heine-Universität Düsseldorf, Institute of Pharmaceutical Biology and Biotechnology, Düsseldorf, North Rhine-Westphalia, Germany.
Lina HoferHeinrich-Heine-Universität Düsseldorf, Institute of Pharmaceutical Biology and Biotechnology, Düsseldorf, North Rhine-Westphalia, Germany.
Ben E WilmesHeinrich-Heine-Universität Düsseldorf, Institute of Pharmaceutical Biology and Biotechnology, Düsseldorf, North Rhine-Westphalia, Germany.
Timur CetinCarl von Ossietzky Universität Oldenburg, University Hospital for Visceral Surgery, Pius-Hospital Oldenburg, Oldenburg, Lower Saxony, Germany.
Irene EspositoUniversity Hospital Düsseldorf, Institute of Pathology, Düsseldorf, North Rhine-Westphalia, Germany.
Dirk WeyheCarl von Ossietzky Universität Oldenburg, University Hospital for Visceral Surgery, Pius-Hospital Oldenburg, Oldenburg, Lower Saxony, Germany.
Johannes StegmaierHeinrich-Heine-Universität Düsseldorf, Center for Digital Medicine, Group Machine Learning for Medical Data, Düsseldorf, North Rhine-Westphalia, Germany.
Nicole E TeuschHeinrich-Heine-Universität Düsseldorf, Institute of Pharmaceutical Biology and Biotechnology, Düsseldorf, North Rhine-Westphalia, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies to date and characterized by a unique immunosuppressive and highly desmoplastic tumor microenvironment (TME). These features drive profound T-cell dysfunction and maintain high resistance to current immunotherapy. By recapitulating the complex 3D architecture of human PDAC, we demonstrate the key immunosuppressive mechanisms that drive T-cell dysfunction within the tumor microenvironment. Method: 3D PDAC spheroids-generated from PANC-1 cells alone or together with primary pancreatic stellate cells (PSC)-were infiltrated with primary human T-cells from healthy donors, allowing controlled analysis of T-cell infiltration, activation, and checkpoint regulation. Furthermore, patient-derived spheroids (PDS) composed of primary tumor cells and cancer-associated fibroblasts were infiltrated with autologous T-cells. Results: Infiltrated T-cells exhibited a pronounced exhaustion signature, including strong upregulation of PD-1, LAG-3, and CTLA-4, closely mirroring the phenotype of tumor-infiltrating lymphocytes (TIL) isolated from PDAC patient samples. Incorporation of pancreatic stellate cells (PSC) generated a fibrotic barrier around the tumor cells that markedly restricted T-cell infiltration, modeling the desmoplastic TME characteristic of PDAC. From a mechanistic perspective, stromal CXCL12-CXCR4 enhanced T-cell exclusion: pharmacological CXCR4 blockade with AMD3100 significantly enhanced T-cell infiltration into PSC-containing spheroids. Furthermore, treatment with the anti-PD-1 monoclonal antibody pembrolizumab partially restored the effector cell function of T-cells within the 3D system. These results demonstrate that this minimalistic platform is capable of capturing complex, cytokine- and stroma-driven immunomodulation typically observed only in advanced organoid or Conclusion: Together, our findings identify critical determinants of T-cell dysfunction in PDAC and introduce a versatile, animal-free 3D model that powerfully captures hallmark immune-evasion mechanisms in PDAC. This system provides a scalable and mechanistically faithful tool for dissecting TME-driven immune suppression and for accelerating the functional evaluation of immunotherapeutic strategies, including patient-tailored approaches.

Indexed as

Carcinoma, Pancreatic DuctalImmune Checkpoint InhibitorsPancreatic NeoplasmsProgrammed Cell Death 1 ReceptorReceptors, CXCR4T-LymphocytesBenzylaminesCell Line, TumorChemokine CXCL12CyclamsHeterocyclic CompoundsHumansLymphocytes, Tumor-InfiltratingPancreatic Stellate CellsSpheroids, CellularStromal CellsBenzylaminesChemokine CXCL12CXCR4 protein, humanCyclamsHeterocyclic CompoundsImmune Checkpoint InhibitorsPDCD1 protein, humanplerixaforProgrammed Cell Death 1 ReceptorReceptors, CXCR4CXCR4immune checkpointspancreatic ductal adenocarcinomapatient-derived spheroidsPD-1T-cell exclusionT-cell exhaustiontumor microenvironment

Identifiers

PMID42553398
PMCPMC13433858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.